Global law firm K&L Gates LLP represented the underwriters in connection with the $220 million initial public offering of Forward Pharma A/S, a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis. Forward Pharma issued 10.5 million American Depositary Shares (ADSs), representing the company’s ordinary shares at a price to the public of $21 per ADS. The ADSs now trade on the NASDAQ Global Select Market under the ticker symbol “FWP”.
Leerink Partners LLC, Jefferies LLC, and RBC Capital Markets, LLC acted as joint book-running managers. JMP Securities LLC acted as co-manager.
Orange County corporate partners David Allen and David Lee led the K&L Gates team that advised the underwriters, with support from Orange County intellectual property partner Louis Cullman, Research Triangle Park FDA partner Michael Hinckle, and corporate associates Barry Spatzer (Washington, D.C.) and Matthew Susson (Orange County).
Source: www.klgates.com
